Abstract
Two groups of children on therapy with monofluoroquinolones were enrolled in this open trial: 169 patients with cystic fibrosis (exacerbation period) and 55 patients with aplastic anemia (neutropenic phase); age was from 6 months to 16 years. The aim of the study was to compare tolerability (with the focus on arthrotoxicity) of ciprofloxacin, ofloxacin and pefloxacin during intermittent (15–50 mg/kg/day in cystic fibrosis patients) and prolonged continuous therapy (10–15 mg/kg/day in patients with aplastic anemia). Quinolone-induced arthropathy was reported in 8.4% of all cases, mainly during pefloxacin therapy (31.8%), and more frequently in patients with aplastic anemia (10.9% vs. 7.7%), only in pubertal children, and was fully reversible with no influence on the linear growth. Following the monofluoroquinolones use, residual jointrelated symptoms were not observed because monofuoroqinolones did not achieve chondrotoxic concentrations in cartilaginous structures.
-
1.
Schmidt M., Hoffmann K. The use of quinolones in children – toxicological aspects. Adv Antimicrob Antineopl Chemother 1992; 11:251-5.
-
2.
Урбах В.Ю. Статистический анализ в биологических и медицинских исследованиях. М.: Медицина; 1975.
-
3.
Семыкин С.Ю. Эффективность и безопасность применения ципрофлоксацина при лечении обострений бронхолегочного процесса у детей с муковисцидозом. Автореф. дис. канд. мед. наук. М., 2002.
-
4.
Schaad U. Toxicity of quinolones in pediatric patients. Adv Antimicrob Antineopl Chemother 1992; 11:236-65.
-
5.
Schaad U. Use of quinolones in pediatrics. Drugs 1993; 45:37-41.
-
6.
Stahlmann R., Foster C., Sickle D. Quinolones in children: are concerns over arthropathy justified? Drug Safety 1993; 6:397-403.
-
7.
Schaad U. Use of the new quinolones in pediatrics. Isr J Med Sci 1994; 30:463-9.
-
8.
Schaad U. Use of the quinolones in pediatrics. In: The Quinolones. Adriole V.T., ed., London; New York: Academic press; 1998.
-
9.
Dellamonica P., Dunais B. Tolerability of fluoroquinolones. Focus on pefloxacin. Clin Drug Invest 1996; 11:3642.
-
10.
Wilson A.P.R., Gruneberg R. Safety and pediatric use. In: Ciprofloxacin: 10 years of clinical experience. Oxford: Maxim Medical; 1997.
-
11.
Wilcox M. A question of toxicity: antimicrobial development – the Libra approach. J Antimicrob Chemother 1999; 3:6-16.
-
12.
Белобородова Н.В., Падейская Е.Н., Бирюков А.В. Фторхинолоны в педиатрии - за и против. Педиатрия 1996; 2:76-84.
-
13.
Авцын А.П., Жаворонков А.А. Патология флюороза Новосибирск: Наука; 1981.
-
14.
Авцын А.П., Жаворонков А.А., Строчкова Л.С. Микроэлементозы человека. М.: Медицина; 1991.
-
15.
Goodman L., Gilman A. Fluoride. In: The pharmacological basis of therapeutics. New York: MacMillan Publishing Company; 1985.
-
16.
Whitford G. Acute and chronic fluoride toxicity. J Dent Res 1992; 71:1538–40.
-
17.
Dequeker I., Declerek K. Fluor in the treatment of osteoporosis. An overview of thirty years clinical research. Schweiz Med Wochenschr 1993; 27:2228–34.
-
18.
Schluter G. Toxicology of ciprofloxacin. In: 1th Internat. Ciprofloxacin Workshop. Excepta Medica; 1986; 61–7.
-
19.
Stahlmann R., Lode H. Safety overview (toxicity, adverse effects and drug interactions). In: The Quinolones. Andriole V.T., ed. London; New York: Academic Press; 1998.
-
20.
Родин В.А., Фролова Г.И., Пинелис Т.П. Геохимическая характеристика Читинской области по содержанию фтора в почвенной воде. Труды Читинского государственного медицинского института. 1990; 133-4.